ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
thecount1
|
1.4K |
355K |
24 |
13/05/24 |
13/05/24 |
ASX - By Stock
|
1.4K
|
355K
|
24
|
|
ASX - By Stock
|
PAA |
Re:
Top 100 PAA Shareholders as at 31 May 2003.
|
|
thecount1
|
20 |
6.3K |
3 |
05/06/23 |
05/06/23 |
ASX - By Stock
|
20
|
6.3K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C and Quarterly Update
|
|
thecount1
|
29 |
6.5K |
7 |
05/05/22 |
05/05/22 |
ASX - By Stock
|
29
|
6.5K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C and Quarterly Update
|
|
thecount1
|
29 |
6.5K |
6 |
05/05/22 |
05/05/22 |
ASX - By Stock
|
29
|
6.5K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C and Quarterly Update
|
|
thecount1
|
29 |
6.5K |
21 |
05/05/22 |
05/05/22 |
ASX - By Stock
|
29
|
6.5K
|
21
|
|
ASX - By Stock
|
PAA |
Re:
Top 100 Shareholders as at 30 April 2022 - With Variations
|
|
thecount1
|
34 |
8.7K |
9 |
05/05/22 |
05/05/22 |
ASX - By Stock
|
34
|
8.7K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C and Quarterly Update
|
|
thecount1
|
29 |
6.5K |
6 |
05/05/22 |
05/05/22 |
ASX - By Stock
|
29
|
6.5K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Phase 3 Canines Lymphoma B Trial ( what to expect)
|
|
thecount1
|
98 |
21K |
1 |
19/04/22 |
19/04/22 |
ASX - By Stock
|
98
|
21K
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Phase 3 Canines Lymphoma B Trial ( what to expect)
|
|
thecount1
|
98 |
21K |
10 |
19/04/22 |
19/04/22 |
ASX - By Stock
|
98
|
21K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Key Appointment to Progress MPL COVID-19 Clinical Trial
|
|
thecount1
|
167 |
38K |
5 |
13/04/22 |
13/04/22 |
ASX - By Stock
|
167
|
38K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Key Appointment to Progress MPL COVID-19 Clinical Trial
|
|
thecount1
|
167 |
38K |
4 |
13/04/22 |
13/04/22 |
ASX - By Stock
|
167
|
38K
|
4
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III
|
|
thecount1
|
1.4K |
372K |
6 |
08/04/22 |
08/04/22 |
ASX - By Stock
|
1.4K
|
372K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Article of General Interest
|
|
thecount1
|
12 |
2.5K |
8 |
02/04/22 |
02/04/22 |
ASX - By Stock
|
12
|
2.5K
|
8
|
|
ASX - By Stock
|
DRX |
Re:
Ann: Galalar PFS and Maiden Ore Reserve
|
|
thecount1
|
42 |
17K |
1 |
01/03/22 |
01/03/22 |
ASX - By Stock
|
42
|
17K
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Epichem Confirms Effectiveness of OHD E-Waste Project
|
|
thecount1
|
50 |
8.9K |
7 |
16/02/22 |
16/02/22 |
ASX - By Stock
|
50
|
8.9K
|
7
|
|
ASX - By Stock
|
ICL |
Re:
Ann: Deep Well Diamond Drilling Results
|
|
thecount1
|
18 |
8.0K |
4 |
04/02/22 |
04/02/22 |
ASX - By Stock
|
18
|
8.0K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C and Quarterly Update
|
|
thecount1
|
60 |
13K |
9 |
03/02/22 |
03/02/22 |
ASX - By Stock
|
60
|
13K
|
9
|
|
ASX - By Stock
|
DRX |
Re:
Ann: Diatreme Discovers 2nd Major High-Grade Silica Deposit
|
|
thecount1
|
31 |
9.5K |
1 |
14/01/22 |
14/01/22 |
ASX - By Stock
|
31
|
9.5K
|
1
|
|
ASX - By Stock
|
ICL |
Re:
Ann: Upcoming Escrow Expiry
|
|
thecount1
|
29 |
10K |
3 |
08/12/21 |
08/12/21 |
ASX - By Stock
|
29
|
10K
|
3
|
|
ASX - By Stock
|
VTG |
Re:
Ann: VTG - Guidance for H1 FY22
|
|
thecount1
|
28 |
21K |
0 |
03/12/21 |
03/12/21 |
ASX - By Stock
|
28
|
21K
|
0
|
|
ASX - By Stock
|
VTG |
Re:
Ann: VTG - Guidance for H1 FY22
|
|
thecount1
|
28 |
21K |
0 |
03/12/21 |
03/12/21 |
ASX - By Stock
|
28
|
21K
|
0
|
|
ASX - By Stock
|
DRX |
Re:
Share Price
|
|
thecount1
|
40 |
14K |
1 |
03/12/21 |
03/12/21 |
ASX - By Stock
|
40
|
14K
|
1
|
|
ASX - By Stock
|
VMS |
Re:
Ann: Date of AGM and Closing Date for Director Nominations
|
|
thecount1
|
110 |
31K |
0 |
10/10/21 |
10/10/21 |
ASX - By Stock
|
110
|
31K
|
0
|
|
ASX - By Stock
|
VMS |
Re:
Why Governments Will Support "VMS"
|
|
thecount1
|
79 |
20K |
4 |
07/10/21 |
07/10/21 |
ASX - By Stock
|
79
|
20K
|
4
|
|
ASX - By Stock
|
LBT |
Re:
Ann: Investor Webinar Presentation
|
|
thecount1
|
16 |
5.1K |
2 |
10/09/21 |
10/09/21 |
ASX - By Stock
|
16
|
5.1K
|
2
|
|